We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Methylation‐regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications L. Calabrò and E. Fonsatti contributed equally to this work.
- Authors
Luana Calabrò; Ester Fonsatti; Maresa Altomonte; Laura Pezzani; Francesca Colizzi; Paola Nanni; Valter Gattei; Luca Sigalotti; Michele Maio
- Abstract
Primary effusion lymphoma (PEL) is a large B‐cell neoplasm with an unfavorable prognosis and limited therapeutic options. In this study, cancer testis antigens (CTA) were investigated as potential immunotherapeutic targets in patients with PEL. Baseline expression of a panel of 11 CTA was highly heterogeneous among five PEL cell lines. In particular, the investigated CTA were not expressed in BC‐2 and BC‐3 cells, while BC‐1, HBL‐6, and BCBL‐1 cells tested positive for 6, 8, and 9 CTA, respectively. The DNA hypomethylating agent 5‐aza‐2′‐deoxycytdine (5‐AZA‐CdR) invariably induced or up‐regulated the expression of all investigated CTA in all cell lines analyzed. The de novo expression of CTA was still detectable at mRNA and protein level at least 2 months after the end of 5‐AZA‐CdR treatment. These findings, and the concomitant up‐regulation of HLA‐class I antigens and ICAM‐1 by 5‐AZA‐CdR, support its clinical use to set‐up innovative chemo‐immunotherapeutic approaches in PEL. © 2004 Wiley‐Liss, Inc.
- Subjects
LYMPHOMAS; CANCER immunotherapy; CANCER cells; CELL lines
- Publication
Journal of Cellular Physiology, 2005, Vol 202, Issue 2, p474
- ISSN
0021-9541
- Publication type
Article
- DOI
10.1002/jcp.20133